The New York Entrepreneur

: Halo Therapeutics stock drops following weak 2023 outlook

Read Time:36 Second

Halozyme Therapeutics Inc. HALO stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8% after hours, following a 1.2% gain to close the regular session at $55.70. The company forecast annual adjusted earnings of $2.50 to $2.65 a share on revenue of $815 million to $845 million with royalties of $445 million to $455 million. Analysts surveyed by FactSet had forecast $2.55 a share on revenue of $892.5 million with royalties of $478.2 million.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Disney is making it easier for its most loyal customers to visit its theme parks
Next post : Pay ranges aren’t too ‘ridiculous’ as transparency laws take effect, report finds